VBI VACCINES INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.63 USD | -3.02% |
|
+1.61% | +7.23% |
| May. 15 | Earnings Flash (VBIV) VBI VACCINES Reports Q1 Revenue $1.2M | MT |
| Apr. 16 | VBI Vaccines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Presenter SpeechSteven Seedhouse (Analysts)Okay. Great. Well, as participants are continuing t...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
VBI Vaccines Inc. is a commercial-stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology and a proprietary mRNA-launched eVLP (MLE) platform technology, the Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The Company is focused on targeting and overcoming significant infectious diseases, including hepatitis B (HBV), coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). Its product pipeline includes an approved vaccine and multiple late- and early-stage investigational programs. PreHevbrio is its approved vaccine for hepatitis B. Its Prophylactic Candidates for coronavirus disease include VBI-2901, VBI-2905, VBI-2902, and others. VBI-1501 is its Prophylactic Candidate for cytomegalovirus. VBI-2601 and VBI-1901 are the therapeutic candidates for HBV and GBM.
Calendar
2024-06-25
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.63
USD
Average target price
5
USD
Spread / Average Target
+693.65%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.23% | 18.63M | |
| +33.63% | 50.85B | |
| -0.09% | 42.82B | |
| +49.62% | 42.03B | |
| -4.96% | 29.55B | |
| +11.18% | 26.11B | |
| -21.95% | 19.13B | |
| +8.61% | 13.05B | |
| +28.31% | 12.16B | |
| +24.73% | 12.08B |
- Stock Market
- Equities
- VBIV Stock
- News VBI Vaccines Inc.
- Transcript : VBI Vaccines Inc. - Special Call
